In silico drug combination discovery for personalized cancer therapy

BackgroundDrug combination therapy, which is considered as an alternative to single drug therapy, can potentially reduce resistance and toxicity, and have synergistic efficacy. As drug combination therapies are widely used in the clinic for hypertension, asthma, and AIDS, they have also been proposed for the treatment of cancer. However, it is difficult to select and experimentally evaluate effective combinations because not only is the number of cancer drug combinations extremely large but also the effectiveness of drug combinations varies depending on the genetic variation of cancer patients. A computational approach that prioritizes the best drug combinations considering the genetic information of a cancer patient is necessary to reduce the search space.ResultsWe propose an in-silico method for personalized drug combination therapy discovery. We predict the synergy between two drugs and a cell line using genomic information, targets of drugs, and pharmacological information. We calculate and predict the synergy scores of 583 drug combinations for 31 cancer cell lines. For feature dimension reduction, we select the mutations or expression levels of the genes in cancer-related pathways. We also used various machine learning models. Extremely Randomized Trees (ERT), a tree-based ensemble model, achieved the best performance in the synergy score prediction regression task. The correlation coefficient between the synergy scores predicted by ERT and the actual observations is 0.738. To compare with an existing drug combination synergy classification model, we reformulate the problem as a binary classification problem by thresholding the synergy scores. ERT achieved an F1 score of 0.954 when synergy scores of 20 and -20 were used as the threshold, which is 8.7% higher than that obtained by the state-of-the-art baseline model. Moreover, the model correctly predicts the most synergistic combination, from approximately 100 candidate drug combinations, as the top choice for 15 out of the 31 cell lines. For 28 out of the 31 cell lines, the model predicts the most synergistic combination in the top 10 of approximately 100 candidate drug combinations. Finally, we analyze the results, generate synergistic rules using the features, and validate the rules through the literature survey.ConclusionUsing various types of genomic information of cancer cell lines, targets of drugs, and pharmacological information, a drug combination synergy prediction pipeline is proposed. The pipeline regresses the synergy level between two drugs and a cell line as well as classifies if there exists synergy or antagonism between them. Discovering new drug combinations by our pipeline may improve personalized cancer therapy.

[1]  Ranadip Pal,et al.  Combination therapy design for maximizing sensitivity and minimizing toxicity , 2016, BMC Bioinformatics.

[2]  Olivier Elemento,et al.  A Computational Approach for Identifying Synergistic Drug Combinations , 2017, PLoS Comput. Biol..

[3]  Pierre Geurts,et al.  Extremely randomized trees , 2006, Machine Learning.

[4]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[5]  B. Al-Lazikani,et al.  Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.

[6]  Mickael Guedj,et al.  Analysis of drug combinations: current methodological landscape , 2015, Pharmacology research & perspectives.

[7]  Dennis Wang,et al.  Combenefit: an interactive platform for the analysis and visualization of drug combinations , 2016, Bioinform..

[8]  Krister Wennerberg,et al.  Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies , 2014, Scientific Reports.

[9]  Gaël Varoquaux,et al.  Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..

[10]  Lei Huang,et al.  DrugComboRanker: drug combination discovery based on target network analysis , 2014, Bioinform..

[11]  Xing-Ming Zhao,et al.  A systems biology approach to identify effective cocktail drugs , 2010, BMC Systems Biology.

[12]  Ranadip Pal,et al.  A Kinase Inhibition Map Approach for Tumor Sensitivity Prediction and Combination Therapy Design for Targeted Drugs , 2011, Pacific Symposium on Biocomputing.

[13]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[14]  P. Sanseau,et al.  Systematic prediction of drug combinations based on clinical side-effects , 2014, Scientific Reports.

[15]  Zhiwei Wang,et al.  Down‐regulation of Notch‐1 and Jagged‐1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF‐κB signaling pathways , 2010, Journal of cellular biochemistry.

[16]  Yang Xie,et al.  A community computational challenge to predict the activity of pairs of compounds Citation , 2015 .

[17]  Yair Benita,et al.  An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies , 2016, Molecular Cancer Therapeutics.

[18]  Li-Xuan Qin,et al.  gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. , 2009, Cancer research.

[19]  Hui Liu,et al.  SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets , 2015, Nucleic Acids Res..

[20]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[21]  Michael Peyton,et al.  Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo , 2010, PloS one.

[22]  Huamin Zhang,et al.  Synergy evaluation by a pathway-pathway interaction network: a new way to predict drug combination. , 2016, Molecular bioSystems.

[23]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..